[-] Show simple item record

dc.contributor.authorWilliams, Imanieng
dc.contributor.authorJia, Fangeng
dc.contributor.corporatenameUniversity of Missouri-Columbia. Office of Undergraduate Researcheng
dc.contributor.meetingnameSummer Undergraduate Research and Creative Achievements Forum (2006 : University of Missouri--Columbia)eng
dc.date.issued2006eng
dc.descriptionAbstract only availableeng
dc.descriptionFaculty Mentor: Michael Lewis, Veterinary Medicine and Surgeryeng
dc.description.abstractOne of the newer methods for imaging and treating cancer is pretargeting. Pretargeting is a relatively simple concept to understand. First, a non-radioactive antibody conjugated to streptavidin is injected into the blood stream. The antibody is given time to reach the tumor and then it is cleared from the blood. Next, radioactive small molecules, like biotin, are administered and after a given amount of time, bound to the streptavidin-antibody at tumor site and cleared from the blood. Finally, the subject goes for imaging to get an accurate look at the size and growth of the tumor for possible treatment. One traditional form of imaging/treatment is radioimmunotherapy (RIT). Although antibodies are good at targeting tumor cells, with this approach, they were extremely toxic to the patient. Other limitations of RIT are high uptake into the blood, slow blood clearance, and slow and uneven penetration into tumors. Pretargeting is a good alternative because there is immediate uptake of radioactive material into the tumor and high tumor-to-normal tissue ratios.eng
dc.description.abstractOne of the newer methods for imaging and treating cancer is pretargeting. Pretargeting is a relatively simple concept to understand. First, a non-radioactive antibody conjugated to streptavidin is injected into the blood stream. The antibody is given time to reach the tumor and then it is cleared from the blood. Next, radioactive small molecules, like biotin, are administered and after a given amount of time, bound to the streptavidin-antibody at tumor site and cleared from the blood. Finally, the subject goes for imaging to get an accurate look at the size and growth of the tumor for possible treatment. One traditional form of imaging/treatment is radioimmunotherapy (RIT). Although antibodies are good at targeting tumor cells, with this approach, they were extremely toxic to the patient.  Other limitations of RIT are high uptake into the blood, slow blood clearance, and slow and uneven penetration into tumors. Pretargeting is a good alternative because there is immediate uptake of radioactive material into the tumor and high tumor-to-normal tissue ratios.eng
dc.identifier.urihttp://hdl.handle.net/10355/922eng
dc.publisherUniversity of Missouri--Columbia. Office of Undergraduate Researcheng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. Office of Undergraduate Research. Undergraduate Research and Creative Achievements Forumeng
dc.source.urihttp://undergradresearch.missouri.edu/forums-conferences/abstracts/abstract-detail.php?abstractid=745eng
dc.subjecttumor imagingeng
dc.subjectcancer treatmenteng
dc.subjectpretargetingeng
dc.titleComparison of tumor imaging using antibody pretargeting and conventional methods [abstract]eng
dc.typeAbstracteng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record